Research programme: otitis media therapeutics - Novus Therapeutics

Drug Profile

Research programme: otitis media therapeutics - Novus Therapeutics

Alternative Names: OP 0201; OP-02; OP-02 Surfactant

Latest Information Update: 12 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator otodyne
  • Developer Novus Therapeutics; Otodyne
  • Class Palmitates; Phospholipids; Surfactants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Otitis media

Most Recent Events

  • 02 Apr 2018 Novus Therapeutics plans a phase I trial of OP 02 in Healthy adult volunteers in 2H 2018
  • 02 Apr 2018 Novus Therapeutics plans a phase I trial of OP 02 for Otitis media (In adults) in 1H 2019
  • 02 Apr 2018 Novus Therapeutics plans a phase I trial of OP 02 for Otitis media (In children) in 1H 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top